{"filing":{"accession_number":"0001437749-26-018242","cik":"0001659617","ticker":"MBRX","company_name":"Moleculin Biotech, Inc.","form":"8-K","filing_date":"2026-05-22","report_date":null,"primary_document":"mbrx20260522_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926018242/mbrx20260522_8k.htm"},"events":[{"id":10646,"run_id":9338,"accession_number":"0001437749-26-018242","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The disclosure announces acceptance of an abstract featuring pooled cardiac safety data for Annamycin (the company's lead drug candidate) for poster presentation at the 2026 ASCO Annual Meeting. For a clinical-stage biotech company, positive clinical data presentations at major medical conferences are material to investors assessing development progress and regulatory pathway viability. However, this does not fit neatly into the more specific event categories (it is not an earnings release, executive change, M\u0026A activity, impairment, or litigation), so \"other_material\" is most appropriate.","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-05-22","form":"8-K","submitted_at":null,"items":[{"id":7014,"accession_number":"0001437749-26-018242","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces acceptance of an abstract featuring pooled cardiac safety data for Annamycin (the company's lead drug candidate) for poster presentation at the 2026 ASCO Annual Meeting. For a clinical-stage biotech company, positive clinical data presentations at major medical conferences are material to investors assessing development progress and regulatory pathway viability. However, this does not fit neatly into the more specific event categories (it is not an earnings release, executive change, M\u0026A activity, impairment, or litigation), so \"other_material\" is most appropriate.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:54:12.926168+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7014,"accession_number":"0001437749-26-018242","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces acceptance of an abstract featuring pooled cardiac safety data for Annamycin (the company's lead drug candidate) for poster presentation at the 2026 ASCO Annual Meeting. For a clinical-stage biotech company, positive clinical data presentations at major medical conferences are material to investors assessing development progress and regulatory pathway viability. However, this does not fit neatly into the more specific event categories (it is not an earnings release, executive change, M\u0026A activity, impairment, or litigation), so \"other_material\" is most appropriate.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:54:12.926168+00:00","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-05-22"}]}